A Phase 1 interventional study of Vedolizumab SC in Healthy Volunteers, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-13.
Sponsored by Takeda · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare PK of single dose of vedolizumab SC 108 milligram (mg) administered as PFS vs investigational device.
The drug being tested in this study is called vedolizumab SC. The study will assess the PK, and variability of a vedolizumab SC in a PFS vs investigational device.
This study will include 2 different device delivery presentations in 2 treatment groups. Participants in each treatment group will be randomized to one of the three administration sites: Abdomen, thigh, or arm. The study will enroll approximately 24 participants, including 4 participants allocated to each administration site within each treatment group. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups:
All participants will receive a single dose of study drug on Day 1.
This single center trial will be conducted in the United States. The overall time to participate in this study is approximately 196 days. Participants will be contacted by telephone on Day 168 after their last dose of study drug for a follow-up assessment which will involve the progressive multifocal leukoencephalopathy (PML) questionnaire survey.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has active or latent tuberculosis (TB) as evidenced by the following:
o A diagnostic TB test performed within 30 days of Screening or during the Screening Period that is positive, defined as:
Note: Participants with documented previously treated TB with a negative QuantiFERON test can be included in the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
Drug: Vedolizumab SC
Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
Drug: Vedolizumab SC
Vedolizumab SC liquid.
Also known as: ENTYVIO, KYNTELES, MLN0002
AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vedolizumab SC
Time frame: Day 1 pre-dose and at multiple time points (up to Day 127) post-dose
AUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for Vedolizumab SC
Time frame: Day 1 pre-dose and at multiple time points (up to Day 127) post-dose
Cmax: Maximum Observed Serum Concentration for Vedolizumab SC
Time frame: Day 1 pre-dose and at multiple time points (up to Day 127) post-dose
Participants took part in the study at 1 investigative site in the United states from 22 February 2018 to 28 August 2018.
| Milestone | Group A: Vedolizumab SC PFS | Group B: Vedolizumab SC Investigational Device |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 12 |
| Not completed | 0 | 0 |
| microgram*day per milliliter(mcg*day/mL) | Group A: Vedolizumab SC PFS | Group B: Vedolizumab SC Investigational Device |
|---|---|---|
| AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vedolizumab SC | 433.4 ± 38.3 | 560.3 ± 26.3 |
| mcg*day/mL | Group A: Vedolizumab SC PFS | Group B: Vedolizumab SC Investigational Device |
|---|---|---|
| AUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for Vedolizumab SC | 446.5 ± 36.2 | 594.0 ± 23.6 |
| microgram per milliliter (mcg/mL) | Group A: Vedolizumab SC PFS | Group B: Vedolizumab SC Investigational Device |
|---|---|---|
| Cmax: Maximum Observed Serum Concentration for Vedolizumab SC | 13.70 ± 24.2 | 16.53 ± 26.9 |
Collected over Treatment-emergent adverse events (TEAEs) are adverse events that started after the first dose of study drug and no more than Day 127. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A: Vedolizumab SC PFS | 0/12 (0%) | 1/12 (8.3%) | 9/12 (75%) |
| Group B: Vedolizumab SC Investigational Device | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| Event | Group A: Vedolizumab SC PFS | Group B: Vedolizumab SC Investigational Device |
|---|---|---|
| PneumoniaInfections and infestations | 1/12 | 0/12 |
| Event | Group A: Vedolizumab SC PFS | Group B: Vedolizumab SC Investigational Device |
|---|---|---|
| Injection site painGeneral disorders | 6/12 | 3/12 |
| Upper respiratory tract infectionInfections and infestations | 2/12 | 3/12 |
| HeadacheNervous system disorders | 1/12 | 2/12 |
| Abdominal painGastrointestinal disorders | 0/12 | 1/12 |
| DyspepsiaGastrointestinal disorders | 1/12 | 0/12 |
| Injection site paraesthesiaGeneral disorders | 1/12 | 0/12 |
| EpididymitisInfections and infestations | 1/12 | 0/12 |
| PneumoniaInfections and infestations | 0/12 | 1/12 |
| Urinary tract infectionInfections and infestations | 0/12 | 1/12 |
| Vaginal infectionInfections and infestations | 0/12 | 1/12 |
The safety analysis set included all participants who were enrolled and received 1 dose of study drug.
| Age, Continuous(years) | Group A: Vedolizumab SC PFS | Group B: Vedolizumab SC Investigational Device | Total |
|---|---|---|---|
| Mean | 37.2 ± 13.55 | 33.6 ± 12.52 | 35.4 ± 12.89 |
| Sex: Female, Male(Participants) | Group A: Vedolizumab SC PFS | Group B: Vedolizumab SC Investigational Device | Total |
|---|---|---|---|
| Female | 6 | 6 | 12 |
| Male | 6 | 6 | 12 |
| Ethnicity (NIH/OMB)(Participants) | Group A: Vedolizumab SC PFS | Group B: Vedolizumab SC Investigational Device | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 11 | 11 | 22 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group A: Vedolizumab SC PFS | Group B: Vedolizumab SC Investigational Device | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 3 | 4 |
| White | 10 | 7 | 17 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Group A: Vedolizumab SC PFS | Group B: Vedolizumab SC Investigational Device | Total |
|---|---|---|---|
| United States | 12 | 12 | 24 |
| Weight(kilogram (kg)) | Group A: Vedolizumab SC PFS | Group B: Vedolizumab SC Investigational Device | Total |
|---|---|---|---|
| Mean | 71.35 ± 11.614 | 69.26 ± 10.637 | 70.30 ± 10.944 |
| Height(centimeter (cm)) | Group A: Vedolizumab SC PFS | Group B: Vedolizumab SC Investigational Device | Total |
|---|---|---|---|
| Mean | 170.4 ± 10.08 | 171.0 ± 7.94 | 170.7 ± 8.88 |
| Body Mass Index (BMI)(kilogram per square meter (kg/m^2)) | Group A: Vedolizumab SC PFS | Group B: Vedolizumab SC Investigational Device | Total |
|---|---|---|---|
| Mean | 24.558 ± 3.2381 | 23.603 ± 2.7232 | 24.080 ± 2.9663 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Feb 2018 to primary completion in Jul 2018, 4 months.
Results were first posted in Aug 2019, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab